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Abstract
A number of experiments have demonstrated the antiobesity effects of b3-adrenergic receptor stimulation by promoting thermogenesis
and/or lipolysis. While many studies have been performed in order to develop b3-adrenergic agonists as a novel strategy in the management
of obesity, more information is needed about the mechanisms involved in thermogenesis and the actions of these drugs on adipocyte
differentiation. To address this, the possible thermogenic and antiadipogenic properties of Tertatolol, a b3-adrenergic agonist, in a
diet-induced obesity model has been tested. Animals fed on a high-fat diet gained more weight and fat mass as compared with control and
high-fat fed animals treated with Tertatolol. A RT-PCR was carried out in white adipose tissue specific genes involved in thermogenesis
such as uncoupling proteins (UCPs) and adipogenesis such as peroxisome proliferator-activated receptor (PPARg2), retinoid receptors
(RXRa/RARa), and fatty acid binding protein (aP2). Levels of UCP1 mRNA were augmented in the Tertatolol-treated group as compared
to non-treated high-fat fed animals, while the b3-adrenergic agonist treatment significantly decreased the expression levels of aP2 and
transcription factors such as PPARg2 and the ratio RXRa/RARa as compared to obese rats. Altogether these data suggest that the
antiobesity effects of b3-adrenergic agonists are not limited to the promotion of thermogenesis and/or lipolysis and support the implication
that these b3-adrenergic agonists also affect fat deposition by impairing adipogenesis in white adipose tissue (WAT). © 2001 Elsevier
Science Inc. All rights reserved.
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1. Introduction
Obesity is defined as a state of pathological increased
adipose mass [1], which results from an imbalance between
energy intake and energy expenditure [2]. Current trends for
obesity management involve multiple tactics including be-
havioural therapies, exercise programmes, diets to decrease
energy and fat intake, as well as pharmacological strategies
[3]. In this sense, b3-adrenergic receptors (b3AR) are
known to play an important role in the regulation of energy
balance, promoting energy expenditure by triggering ther-
mogenesis in brown adipose tissue (BAT), and/or lipolysis
in white (WAT) and brown adipose tissues (BAT) [4].
Selective b3-adrenergic agonists are considered as potential
antiobesity drugs, since some of them have been success-
fully applied in animal models and a number of companies
and laboratories are looking for new molecules with affinity
for b3-adrenergic receptors for the management of exces-
sive fat accumulation in humans. Molecules with affinity for
b3-adrenoceptors have been associated with increased en-
ergy expenditure by inducting UCPs [5], lipolysis and de-
creased food intake [4,6] as the most likely mechanisms
contributing to reverse or to delay diet induced obesity
(DIO) in animals [7,8]. Little is known about the effects of
b3-adrenergic agonists on the adipocyte differentiation pro-
cess and the expression of related genes. In this context,
Tertatolol is an aryloxy-propanolamine with high affinity
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for b3 adrenergic receptors, but also with b1 and b2 antag-
onist properties [9,10].
Adipogenesis regulation involves different transcription
factors which function cooperatively to transactivate adipo-
cyte genes bringing about adipocyte differentiation [11].
The transcription factor, PPARg2, a member of the perox-
isome proliferator-activated receptor subfamily of nuclear
hormone receptors [12], heterodimerizes with retinoid X
receptors (RXR) resulting in the promotion of gene tran-
scription by binding to DNA recognition motifs of specific
genes. The PPARg2-RXRa heterodimere plays a critical
role in the adipocyte differentation process and in the main-
tenance of the fully differentiated adipocyte phenotype by
enhancing the expression of mature adipocyte marker genes
such as aP2 [11,13]. Accordingly, the activation of PPARg2
constitutes an important part of the mechanism behind the
adipogenic effect of overfeeding and high fat diet [14]. The
focus of this study is on the molecular effects of a b3-
adrenergic agonist (Tertatolol) on WAT mRNA expression
of UCP1, UCP2, UCP3, aP2, PPARg2 and the RXRa/
RARa ratio in a diet-induced obesity model, which is
known to promote adipocyte hypertrophy [8] and PPARg2
expression [14].
Therefore, current work evaluates the proposal that the
antiobesity effects of the b3-adrenergic agonists (Tertato-
lol), involve modifying the expression of adipogenic tran-
scription factors in addition to promote UCP expression.
Furthermore, potential associations between PPARg2, aP2
and UCPs were also investigated in order to find potential
interaction mechanisms.
2. Materials and methods
2.1. Animals and diets
Twenty-six female Wistar rats, supplied by the Applied
Pharmacobiology Centre (CIFA-Pamplona, Navarra,
Spain), weighing about 150 g, were housed at 25 6 1° with
a 12-hr light/dark cycle (08:00 to 20:00) and assigned into
three experimental groups. One group of rats was fed on a
standard chow diet (Rodent Toxicologic Diet, B&K Uni-
versal), containing 160 g of protein, 710 g of carbohydrates,
and 30 g of lipid per kg of diet (15204 kJ/kg) for 30 days
(named Lean-Control group, with N 5 10). This lean-
control group was intraperitoneally injected with saline ev-
ery day. Another two groups were fed on a fat-rich high-
energy diet (High-Fat diet, HFD), whose components were
pate, bacon, chips, cookies, chocolate, and chow with pro-
portions 2:1:1:1:1:1, which was given to each rat per day as
published elsewhere [9,15]. The macronutrient composition
of the high-fat diet was 103 g of protein, 357 g of carbo-
hydrates, and 330 g of lipids, which provided 19614 kJ/kg
of diet. All animals had free access to water and food during
30 days. One HFD group was daily intraperitoneally in-
jected with saline (named High-Fat Control group; N 5 8)
and the other (High-Fat 1 b3; N 5 8) was intraperitoneally
injected every day with Tertatolol (1 mg/kg/day), which is
a new b3-adrenergic agonist with b1 and b2 antagonist
properties [9] for the whole experimental time. After 30
days, rats were starved for 12 hr, euthanized by cervical
dislocation, and their trunk blood was collected. Immedi-
ately, the whole abdominal white adipose tissue (retro and
intraperitoneal, omental and mesenteric sites) was carefully
excised, weighed, frozen in liquid nitrogen and stored at
280°C until analysis. Rectal temperature was also recorded
by a rectal probe (Yellow Springs Instruments) connected to
a Panlab thermometer pb 0331 (Panlab).
All experimental procedures were performed according
to national and institutional guidelines for animal care and
use at the University of Navarra.
2.2. Serum measurements
Serum leptin was determined with a correlate-EIA kit
(rat leptin Enzyme Immunometric Assay Kit, Assay De-
signs, Inc.) following standard procedures. Glucose was
measured with the commercial kit Unimate 7 PAP (Roche)
and free fatty acids by the NEFA C ACS-ACOD Method
(Waco Chemicals USA, Inc.). The glucose and fatty acid
kits were adapted for a COBAS MIRA (Roche) equipment.
Serum insulin was measured with a commercially available
RIA kit (Rat Insulin [125I] assay system, Amersham) as
indicated by the supplier.
2.3. Extraction of total RNA and semiquantitation by
reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNA was isolated by the Ultraspec-II RNA Isola-
tion System (Biotecx Laboratories) from 150 mg of fat
tissue. After 30-min treatment with 10 units of RNase-free
Dnase I (Boehringer Mannheim), 1.5 mg of RNA were used
to synthesis first-strand complementary DNA (c-DNA). The
RT reaction was carried out in a volume of 30 mL contain-
ing 50 mmol/L Tris HCl (pH 8.3), 75 mmol/L KCl, 3 mM
MgCl2, 10 mmol/L dithiothreitol, 100 ng of random hex-
amers (Boehringer Mannheim), 1 mmol/L each DTP (Bio-
line), 20 units of Rnase inhibitor (Promega, Madison, USA),
200 units of M-MLV RT (Gibco BRL, Life Technologies,
Gaithersburg, MD, USA), and incubated at 37° for 60 min.
The enzyme was inactivated by heating at 95° for 5 min.
Four microliters from the RT reaction were amplified in a
50-mL reaction mixture containing 40 ng of each primer, 16
mmol/L(NH4)2SO4, 67 mmol/L Tris HCl (pH 8.8), 2
mmol/L MgCl2, 0.1% Tween-20, 0.2 mmol/L each dNTP,
and 1 unit of BioTaq polymerase (Bioline).
Primers used to amplify UCP1 cDNA (GenBank
M11814) were 59-GTCTTAGGGACCATCACCA-39
(sense, 351–369) and 59-CCAGTGTAGCGGGGTTT-39
(antisense, 629–646); UCP2 (GenBank AF039033) 59-TA
AAGCAGTTCTACACCAA-GGG-39 (sense, 308–329)
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and 59-CGAAGGCAGAAGTGAAGTGG-39 (antisense,
648–667); UCP3 (GenBank U92069) 59-GGAACTGGAG
GCGAGAGGAA-39 (sense, 577–596) and 59-TTTGTA
GAAGGCTGTGGGGC-39 (antisense, 926–945); PPARg2
(GenBank Y12882) 59-TCTGATTATGGGTGAAACTC-39
(sense 43–62) and 59-TTTCTACTCTTTT-TGTGGATC-39
(antisense 592–612); aP2 (GenBank K02109) 59-AACAC
CGAGATTT-CCTTCAA-39 (sense 178–197) and 59-
TCACGCCTTTCATAACACAT-39 (antisense 351–370);
RXRa (GenBank M84817) 59-CACATTGGGCTTCGG
GACT-39 (sense 359–367) and 59-ACTCCACCTCGT
TCT-CATTC-39 (antisense 755–774); RARa2 (GenBank
U15211) 59-GACCGAAACAAA-AAGAAGAAAGA-39
(sense 712–734) and 59-GCAATGGTGAGGGTGGT
GAA-39 (antisense 976–995); b-actin (GenBank J00691)
59-TCTACAATGAGCTGCGTGTG-39 (sense 1599–1618)
and 59-GGTCAGGATCTTCAT-GAGGT-39 (antisense,
2357–2376). Primers for all genes were designed using the
Oligo 4.05 Primer Analysis Software (National Bioscience,
Inc.). cDNA was amplified using the parameters shown in
Table 1.
A first step of denaturation was applied (95° for 30 s) and
a final extension step for all primers at 72° for 7 min in all
cases. To ensure the linearity of PCR reactions and to
validate the cDNA quantitation, adequate controls and stan-
dard curves were carried out by amplifications of 200 ng of
first strand cDNA per reaction from 20 to 40 cycles as
previously reported [16]. Amplifications were linear under
conditions shown in table 1 and were carried out in a
GeneAmp PCR System 2400 (Perkin Elmer). The amplified
products were resolved in a 1.5% Agarose gel with ethidium
bromide. Levels of messenger RNA (mRNA) were mea-
sured as the ratio of signal intensity for each gene relative to
b-actin. PCR band intensities were determined by densito-
metric analysis with the Gel Doc 1000 ultraviolet (UV)
fluorescent gel documentation system and Molecular Ana-
lyst 1.4.1 software for quantitation of images (Bio-Rad,
Hercules).
The use of PCR is a specific strategy to evaluate mRNA
expression, which is supported by the following points:
linearity of the PCR reactions was tested by amplification of
200 ng of first strand cDNA per reaction from 20 to 40
cycles; the data obtained concerning PPARg2, aP2 retinoid
receptors and UCP mRNA are comparable to values in the
literature using the RT-PCR and other methods (Northern
Blot) under different experimental treatments and because it
is generally assumed that RT-PCR determinations tend to
reduce the apparent differences between samples. Further-
more, a number of articles published in highly rated journals
have accepted this methodology [16–22] in order to mea-
sure mRNA expression.
2.4. Statistical analysis
All results are expressed as mean and standard error of
the mean (SEM). Once normality was positively confirmed
by the Kolmogorov-Smirnov test, those data were analysed
using a one-way ANOVA followed by orthogonal contrasts.
The Kruskall-Wallis test followed by a Mann–Whitney U
test multiple comparisons was used when normality was not
confirmed by the Kolmogorov-Smirnov test. The Pearson
correlation coefficient was computed to analyze association
between two variables. The calculations were performed
using the SPSS/Windows version 7.5 (SPSS Inc.) statistical
package. A P value lower than 0.05 was considered to be
statistically significant.
3. Results
3.1. Body weight rectal temperature and serum
determinations
High-fat fed animals significantly increased body and
abdominal fat weights as compared to the controls at the end
of experimental time (Table 2). High-fat fed animals receiv-
ing the b3-adrenergic agonist showed a significant reduction
in body weight as compared to high-fat fed animals, al-
though they did not achieved the weight of the lean-con-
trols. Abdominal fat weight, however, was not significantly
different between b3-adrenergic agonist injected animals
and lean controls (Table 2).
In regard to serum determinations, glucose levels were
significantly elevated in both high-fat fed groups (either
b3-adrenergic agonist treatment or saline injected) as com-
pared to lean controls. Although the administration of the
b3-adrenergic agonist significantly reduced serum leptin
levels with respect to the high-fat fed groups, leptin levels in
the Tertatolol injected group were significantly greater than
in the lean control animals. No statistical differences were
found among experimental groups concerning serum fatty
acid (FA) and insulin serum levels (Table 2). Moreover,
while rectal temperature was slightly higher in the b3-
adrenergic agonist treated group, it did not reach statistical
relevance.
3.2. White adipose tissue (WAT) UCP mRNA expression
levels
The UCP1 mRNA levels in WAT were hardly detectable
in the lean control group, whereas a significant overexpres-
Table 1
Specific conditions used for the amplification of each gene studied
Annealing (s) Elongation (s) No of cycles
UCP1 58°–30 72°–30 33
UCP2 61°–30 72°–30 26
UCP3 55°–45 72°–60 35
PPARg2 53°–35 72°–50 44
aP2 60°–30 72°–30 29
RXRa 57°–30 72°–40 40
RARa 60°–30 72°–30 35
b-actin 59°–30 72°–30 27
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sion was found in the high-fat b3-adrenergic agonist in-
jected group with respect to the high-fat fed saline injected
animals (Table 3).
Levels of UCP2 and UCP3 mRNA were more than
two-fold increased in the high-fat fed group as compared to
lean controls, while the b3-adrenergic agonist treatment did
not induce statistically significant changes in UCP2 and
UCP3 mRNA expression with respect to high-fat fed ani-
mals (Table 3).
3.3. White adipose tissue PPARg2, aP2 expression, and
RXRa/RARa ratio
PPARg2 expression was significantly increased after
high-fat feeding as compared to control fed animals. The
b3-adrenergic agonist treatment (Fig. 1) reduced such
elevation as compared to the high-fat fed group. Simi-
larly, aP2 mRNA expression levels were significantly
elevated in high-fat fed group with respect to the control
group, while Tertatolol treated animals showed statisti-
cally significant lower aP2 levels as compared to the
other high-fat fed group (Fig. 1). The RXRa/RARa ratio
showed significant higher ratios in high-fat fed groups as
compared to control fed animals, whereas the adminis-
tration of the b3-adrenergic agonist significantly de-
creased the RXRa/RARa ratio with respect to the high-
fat fed animals (Fig. 2).
3.4. Associations body fat content, PPARg2, aP2, RXRa,
and UCPs mRNA
Statistically significant associations (Fig. 3) were found
after correlation analyses between PPARg2 and white fat
weight (r 5 0.46, P , 0.01), PPARg2 and aP2 (r 5 0.81,
P , 0.01), PPARg2 and UCPs (r 5 0.62, P , 0.01) and,
also between PPARg2 and RXRa (r 5 0.55, P , 0.01).
Also, a statistically significant correlation between aP2 and fat
weight (P , 0.05) was found (Plot not shown).
4. Discussion
The discovery of the b3-adrenergic receptor as an adi-
pocyte b-adrenoceptor subtype, with thermogenic and lipo-
lytic properties [7] has resulted in the proposal for b3-
adrenergic agonists as one of the possible strategies to
increase energy expenditure [3]. The role of the b3-adreno-
ceptor stimulation in human obesity treatment is still dis-
cussed [23] and numerous groups are seeking additional
b3-adrenergic agonists with high affinity and specificity for
the human b3-adrenoceptor for the possibility of treating
obese individuals. However, the implication of such adre-
noceptor stimulation in the adipocyte differentiation process
is scarcely studied.
High-fat diets have been used to generate diet induced
obesity models (DIO) and to promote adipocyte differenti-
ation in a number of studies [11,14]. In this context, the
administration of the b3-adrenergic agonist (Tertatolol) was
Table 2
Weight and serum determinations
Control High-Fat High-Fat 1 b3 P value
Final body weight (g) 266.3 6 10.9a 308.0 6 20.6b 284.2 6 21.5c p , 0.01
Abdominal fat weight (g) 7.4 6 1.7a 18.9 6 5.8b 12.3 6 5a p , 0.01
Rectal temperature (°C) 37.6 6 0.4 37.4 6 0.2 38.2 6 0.2 p 5 0.15
Serum fatty acids (mmol/L) 0.83 6 0.1 0.72 6 0.05 0.71 6 0.03 n.s.
Serum insulin (ng/mL) 0.88 6 0.14 1.22 6 0.18 1.02 6 0.05 n.s.
Serum glucose (mg/dL) 80.5 6 2.1a 93.3 6 3.7b 90.9 6 3.8b P , 0.05
Serum leptin (ng/mL) 50.1 6 6.5a 121.9 6 7.4b 80 6 12.1c P , 0.01
Data are mean 6 SEM. Rats were assigned into the following groups: Control (control fed and saline injected), High-fat (fed on a high fat diet and saline
injected) and High-fat 1 b3 (fed on a high-fat diet and b3-adrenergic agonist injected).
a,b,c Data not sharing a common superscript are significantly different after statistical analysis.
Table 3
UCPs mRNA expression levels in WAT
Control High-Fat High-Fat 1 b3 P value
UCP1 mRNA levels 0.01 6 0.01a 0.23 6 0.14b 0.64 6 0.31b P , 0.05
UCP2 mRNA levels 0.05 6 0.009a 0.12 6 0.02b 0.11 6 0.03b P , 0.01
UCP3 mRNA levels 0.06 6 0.01a 0.14 6 0.01b 0.09 6 0.03a,b P , 0.05
Data are mean 6 SEM of the ratio between each gene and b-actin. Rats were assigned into the following groups: Control (control fed and saline injected),
High-fat (fed on a high-fat diet and saline injected) and High-fat 1 b3 (fed on a high fat diet and b3-adrenergic agonist injected).
a,b,c Data not sharing a common superscript are significantly different after statistical analysis.
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able to delay fat accumulation in rats fed on a high-fat diet
(HFD). Since Tertatolol has antagonist properties on b1 and
b2 adrenoceptors, which are known to be involved in lipid
mobilisation, it appears as a good strategy to study the role
of b3-adrenergic agonists as antiobesity agents. The low
serum leptin levels observed after the Tertatolol treatment
suggest a down-regulation of leptin by b3-adrenergic ago-
nists through the sympathetic nervous system, as previously
published [24]. Nevertheless, other reports [25,26] indicate
that leptin as an adiposity signal, is lowered after the lipid
mobilisation produced by the b3-adrenergic agonist treat-
ment. In this sense, acute treatment with b3-adrenergic
agonists may inhibit ob gene expression, while long-term
b3-adrenergic agonist administration induces a reduction of
fat deposition, which may further decrease adipocyte leptin
secretion [27].
Long periods of b3-adrenergic agonist treatment have
been reported to promote fatty acid oxidation inside the
adipocyte, thus reducing serum fatty acids levels [16,28] as
it is observed in the current work, although statistical sig-
nificance was not achieved. The lower levels of fatty acids
in high-fat fed animals may also be explained by the fact
that this diet induces fat accumulation at the expense of
circulating fatty acids [16].
The b3-adrenergic agonists are known to promote energy
expenditure by inducing UCP expression in a variety of
tissues, such as brown adipose tissue [7], white adipose
tissue and skeletal muscle [28,29]. Nevertheless, regulation
of each UCP might be differently accomplished by distinct
tissues. In this sense UCP1, primarily expressed in BAT
[12], is strongly induced in WAT after b3-adrenergic ago-
nist treatment [8]. This expression has been attributed to
brown adipocyte appearance among typical white adipose
depots in response to sympathetic stimulation. UCP1 over-
expression may be responsible for the marginal increase in
body temperature observed after the treatment with the
b3-adrenergic agonist, thus supporting the thermogenic ef-
fect of b3-adrenergic agonist. UCP2, another uncoupling
protein with 55% homology of aminoacid sequence of
UCP1, is widely distributed in different tissues, including
WAT, BAT, skeletal muscle, liver, kidney, lung and the
immune system [1]. While high-fat diet consumption and
adiposity significantly increased UCP2 mRNA expression
in WAT, as previously reported [30,31], the administration
of the b3-adrenergic agonist failed to induce any additional
overexpression in high-fat fed animals [28,32]. Consistent
with this idea, dietary fat or an adiposity sensor, such as
leptin, may contribute to the regulation of UCP2 expression
in WAT [33] rather than sympathetic signals. The third
member of the uncoupling protein family is UCP3, which is
expressed in skeletal muscle, BAT and, at low levels, in
heart and WAT [31,33]. High-fat feeding for long periods
increased WAT UCP3 mRNA levels, whereas Tertatolol
treatment slightly reduced such elevation.
In order to investigate the potential implication of the
b3-adrenergic receptor stimulation in adipogenesis, the ex-
pression of PPARg2, which is known to regulate adipocyte
differentiation, was analysed after Tertatolol treatment.
PPARg2 is one of the most important transcription factor
regulating fat cell differentiation [11], mediating high-fat
diet induced adipocyte hypertrophy [34]. As some other
nuclear receptors, it heterodimerizes with the retinoid X
receptor (RXR) to regulate adipogenesis [12] as well as to
control the expression of adipocyte specific genes such as
aP2 involved in the maintenance of adipocyte phenotype
[11–13]. In this sense, measuring PPARg2 mRNA expres-
sion may provide insights on how dietary fat intake and
b3-adrenergic agonist could affect the adipocyte differenti-
ation process.
High-fat feeding induced a significant increase in fat pad
weights, which is probably due to adipocyte hypertrophy
[8]. Such effect may be mediated by PPARg2 [34] as
Fig. 1. PPARg2 and aP2 mRNA expression levels in white adipose tissue
in lean, control-fed rats (Control; h), high-fat fed rats (HF; o), high-fat fed
administered with b3-adrenergic agonist rats (high-fat fed 1 b3; n ). Data
are mean 6 SEM of the ratio between each gene and bactin. Bars represent
Standard Error of each Mean (SEM). a,b,c Data not sharing a common
superscript are significantly different after statistical analysis.
Fig. 2. RXRa/RARa mRNA expression levels in white adipose tissue in
lean, control fed rats (Control; h), high-fat fed rats (HF; o), high-fat fed
b3 injected rats (high-fat fed 1 b3; n ); Data are mean 6 SEM of the ratio
between each gene and bactin. Bars represent Standard Error of each Mean
(SEM). a,b,c Data not sharing a common superscript are significantly dif-
ferent after statistical analysis.
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suggested by the significantly elevated mRNA levels and
the positive significant correlation found with the body fat
content of animals. Furthermore, the high-fat feeding in-
duced increase in PPARg2 mRNA levels was blunted in
Tertatolol treated animals, resulting in only a minor eleva-
tion of fat pad weight. A similar expression pattern was also
observed when aP2 mRNA levels were analysed. These
results suggest that Tertatolol may exert a negative effect on
PPARg2, and aP2 mRNA expression. In this sense, the
present data are consistent with the hypothesis that b3-
adrenergic agonists are able to impair adipogenesis proba-
bly by decreasing mRNA expression of genes specifically
involved in adipocyte differentiation and phenotype main-
tenance.
Retinoic acid receptors are nuclear receptors involved in
adipocyte differentiation, which includes RXRa and RARa.
RXRa transcription factor induces adipogenesis by het-
erodimerizing with PPARg2, while RARa blocked adipo-
cyte differentiation because it binds to RXRa, avoiding
RXRa-PPARg2 heterodimerization [35]. In this sense, the
RXRa/RARa ratio was calculated because high ratios in-
dicate that RXRa is promoted over RARa expression, thus
favouring adipogenesis, whereas low ratios mean the oppo-
site, indicating that adipogenesis is inhibited [36]. Our re-
sults confirm this hypothesis, since the RXRa/RARa ratio
in the high-fat fed animals are significantly higher than the
ratio obtained from control fed animals. Furthermore, Ter-
tatolol treatment significantly reduced the RXRa/RARa
ratio, suggesting that differentiation is promoted by high-fat
diet with respect to the other groups, whereas the b3-adren-
ergic agonist appears to delay or block the adipogenic effect
of the high-fat diet.
In addition, statistically significant associations between
PPARg2 with RXRa and aP2 were found, as might be
expected because the close physiological function of these
genes in adipocytes. Interestingly, the significant associa-
tion found between PPARg2 and UCP3 may suggest a
possible regulatory role of PPARg2 on the UCP3 expres-
sion. The identification of a functional peroxisome prolif-
erator responsive element (PPRE) in the promotor region of
UCP3 [37] supports this hypothesis.
In summary, the high-fat diet intake promoted adipocyte
growth, thus increasing total body weight and expression of
adipogenic transcription factor. The b3-adrenergic agonist,
Tertatolol, appears to delay the development of a diet-
induced obesity by increasing energy expenditure and by
Fig. 3. Statistical associations. (a) PPARg2 with aP2; (b) PPARg2 with UCP3; (c) PPARg2 with RXRa in WAT; (d) PPARg2 with abdominal fat weight.
Analyses were developed using the Pearson correlation test. **P , 0.01; *P , 0.05.
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impairing adipogenesis. This is supported by the findings
that b3-adrenergic agonist administration reduced the
RXRa/RARa ratio, the adipocyte specific gene, aP2, and
PPARg mRNA levels, which negatively affect adipogene-
sis. This information is of interest in biochemical pharma-
cology and for the development of new molecules with
specific application in human obesity.
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